Navigation Links
Telik Announces Publication of Review Focused on the Inhibition of the Enzyme GSTP1-1 as a Target for New Cancer Treatments
Date:7/12/2010

PALO ALTO, Calif., July 12 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced the publication of a review in the journal, Cell Death and Differentiation: Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death; http://www.nature.com/cdd/journal/vaop/ncurrent/full/cdd201080a.html.  This review describes recent advances in the understanding of the important role that the enzyme GSTP1-1 plays in the progression of cancer and other diseases associated with increased cell proliferation.  Telintra®, Telik's investigational drug candidate inhibitor of GSTP1-1, has recently been reported to show positive results in a Phase 2 trial in patients with MDS, a disease characterized by disordered cell proliferation and differentiation.  Reprints of the publication are available from Telik.  

Background on MDS

The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis (blood cell production) involving one or more cell lineages (red blood cells, white blood cells or platelets) and a variable risk of transformation to acute myeloid leukemia (AML).  MDS becomes more common with age.  It is estimated that MDS affects approximately 300,000 people worldwide.  According to the American Cancer Society, 10,000–20,000 new cases of MDS are diagnosed each year in the United States, with survival rates ranging from six months to six years.  MDS patients often require blood transfusions to manage their disease.

There remains a critical need for effective, well tolerated therapies for MDS.  Telintra has a novel mechanism of action that inhibits an enzyme called glutathione S-transferase P1-1 which may activate JNK kinase, a key regulator of cellular growth and differentiation of blood precursor cells.  Telintra has been shown to stimulate normal multilineage differentiation of blood stem cell precursors and induce cancer cell death, or apoptosis, in human leukemia cell lines.  Additional information on Telintra is available at www.telik.com.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candidates in clinical development are Telintra, a modified glutathione analog for the treatment of MDS and Severe Chronic Neutropenia (SCN), and Telcyta®, a cancer activated prodrug for the treatment of advanced non-small cell lung cancer and ovarian cancer.  Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Telik Announces Publication of a Case Report of a Sustained Hematologic Response in Myelodysplastic Syndrome Following an Abbreviated Exposure to Oral Telintra(R) (Ezatiostat HCl)
2. Telik Announces Fourth Quarter and 2009 Year End Financial Results and 2010 Financial Guidance
3. Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revlimid(R)) in Patients With Myelodysplastic Syndrome (MDS)
4. Telik Announces Third Quarter 2009 Financial Results
5. Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
6. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
7. Telik Announces Presentation at ASCO Annual Meeting
8. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
9. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
10. Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
11. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... Datascope Corp. is voluntarily performing a worldwide field correction of certain ... failure code.     ... PART NUMBER ... 0998-UC-0446HXX; 0998-UC-0479HXX 0998-00-3013-XX;  0998-UC-3013-XX ... This field correction also applies to any ...
(Date:6/14/2017)...  ivWatch LLC, a medical device company focused on ... is pleased to announce it was the Bronze Winner ... and Equipment at the 2017 Medical Design Excellence Awards ... The award was presented by Medical Device and Diagnostics ... New York during MD&M East, ...
(Date:6/14/2017)... N.C. , June 14, 2017  In 2016, ... Creative Startups pitch competition and came away ... reality platform is described by Forbes as "entering the ... American Medical Association as teaching "empathy to medical professionals ... the startup was recently named a finalist for the ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... American Farmer proudly announces the participation of ... winning television series, scheduled to broadcast fourth quarter 2017. American Farmer airs Tuesdays at ... supplier of garden pea seed. As demand grew, the small company located in Moscow, ...
(Date:6/28/2017)... Gainesville, VA (PRWEB) , ... June 28, 2017 ... ... asset protection assistance and financial consultations to communities in northern Virginia and DC, ... Center to help provide for patients with Alzheimer’s and other disorders that lead ...
(Date:6/27/2017)... Zurich, Switzerland (PRWEB) , ... June 27, 2017 , ... ... crowd to manage token assets on the Ethereum blockchain, has released their technical ... but until now, there has been little systematic approach for determining which offerings will ...
(Date:6/27/2017)... ... June 27, 2017 , ... A January 18th ... to reach a staggering $6.81 billion by the year 2024 according to a new ... faster rate than those made from titanium. Los Angeles area clinic Beverly Hills Periodontics ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... Foundation Fundraiser hygiene symposium in Mystic, CT. Covering the process and maintenance strategies ... experience in these popular periodontal procedures. Drs. Toback and Urbanski practice as experienced ...
Breaking Medicine News(10 mins):